Anmol Singh, MD
@MDanmolsingh
Heme/Onc at @VCSpecialists passionate about taking care of patients with breast cancer. Trained by @DukeIMResidency & @MDAndersonNews. Views my own. she/her
You might like
Reminder-2022 @ASCO Guideline: Adjuvant Bisphosphonate Use in Early Breast Cancer 📌Adjuvant bisphosphonate therapy should be discussed with all postmenopausal (natural or therapy-induced) patients with early-stage breast cancer, regardless of HR or HER2 status, who are…
Great algorithm! #bcsm
Joined @DrHBurstein contest during #ESMO25 @myESMO review: proposed algorithm for first- and second-line #EndocrineTherapy in ER-positive/HER2-negative metastatic #BreastCancer @OncoAlert
There is understandable power to 'global' oncology trials, but sponsors need to assure appropriate standards of care are met. In DB-11, > 40% of pts with residual HER2+ BC did not get TDM1, the standard since 2019. It means EFS data are and will be hard to interpret.
Absolutely terrific discussion by Dr. Ana Garrido-Castro @DFCI_BreastOnc of ASCENT-03 and TROPION-Breast02. Trop2 ADCs moving to the 1L setting in met TNBC not eligible for IO.
Important to point out that the KATHERINE and DB-05 populations are very different. - KATHERINE: any residual invasive dz - DB05: inoperable or node-positive residual dz (very high risk) In the future, we will have TWO SoC adjuvant treatments for RD, depending on risk
#ESMO25 💥DESTINY-Breast05 💥 T-DXd vs T-DM1 in residual high-risk HER2+ early BC: ✅️IDFS: 6.2 % vs 12.5 % → HR 0.47 ILD: 9.6 % (2 G5) vs 1.6 %! 💬 T-DXd substantially lowered recurrence risk vs T-DM1 — likely the new post-neoadjuvant standard. Full data eagerly awaited
#datroway improves OS and PFS for 1L TNBC compared to investigator choice chemo. Another study in the arsenal where ADC beats chemo! #bcsm astrazeneca.com/media-centre/p…
A nice review on Postmastectomy RT and RNI in the era of de-escalation of treatment #bcsm doi.org/10.1200/OP-25-… @ErikaHamilton9 @DrAGraff @stolaney1 @hoperugo @matteolambe @jamecancerdoc @drsarahsam @JankovicK @antgiorda @DrHBurstein @nlinmd @BianchiniGP @Dr_RShatsky…
Multiple studies looking at neoadjuvant regimens for HER2+ early BC. Looks like THP would suffice for most stage 1 and 2, and Cb not needed. Interesting question as to whether 6 cycles / 18 weeks is > than 4 cycles / 12 weeks. @ASCO #ASCO25 @OncoAlert
Presented at #ASCO25: In the OASIS-4 phase 3 trial involving women taking endocrine therapy for HR-positive breast cancer, elinzanetant (a neurokinin-targeted therapy) significantly reduced the frequency of moderate-to-severe vasomotor symptoms. Full trial results:…
📌 Do We "Node" What to Do About the Axilla❓ Great discussion👏🏻 ✨Mediget Teshome, MD, FACS, MPH @OncoAlert #OncoAlertAF #ASCO25
Dr Sonya Reid makes excellent point in Metastatic TNBC Sadly 50% of patients do not make it to second line therapy in mTNBC. In that case, waiting beyond first line to give a more effective regimen seems silly. #bcsm #ASCO25
📌 The TRADE study: A phase 2 trial to assess the tolerability of abemaciclib dose escalation in early-stage HR+/ HER2- breast cancer. ✨Erica L. Mayer, MD, MPH, FASCO ✔️Rapid Oral Abstract Session Breast Cancer-Local/Regional/ Adjuvant @OncoAlert #OncoAlertAF #ASCO25 #Day3
Dr. Frank Sinicrope presents ATOMIC, chemo +/- atezolizumab as adjuvant tx for Stage III dMMR colon cancer. 54% of patients high risk (T4/N2). 3-year DFS 86.4 vs 76.6%, HR 0.50 (P<0.0001) @ALLIANCE_org #ASCO25
Atezo arm with doubling of G4 neuropathy (14 vs 7%) and more patient deaths. Do these patients need oxaliplatin? #ASCO25
Dr. Myriam Chalabi discusses ATOMIC, pointing out it's the most meaningful adjuvant data since the IDEA collaboration was presented at the ASCO Annual Meeting in 2017, and asks the right questions in this space: #ASCO25
Dr. Chalabi proposes that lower risk tumors get treated with surgery, chemo/IO per ATOMIC and higher risk tumors consider neoadjuvant IO per NICHE-2. #ASCO25
Dr. Myriam Chalabi discusses ATOMIC, pointing out it's the most meaningful adjuvant data since the IDEA collaboration was presented at the ASCO Annual Meeting in 2017, and asks the right questions in this space: #ASCO25
1st Plenary #ASCO25: #ATOMIC Ph III, adj mFOLFOX + Atezolizumab vs. mFOLFOX in Stg III dMMR colon ca. - 3yr DFS 86.4% vs 76.6% (HR 0.50), benefit seen in all subgroups. DFS 100% in Niche2 - ⬆️ discontinuation w/ Atezo - OS not mature - ⬆️ Gr4 neutropenia - To Adj or to NeoAdj?
.@NRGonc BR003 shows adding carboplatin to weekly paclitaxel following DD AC for adj tx of node-positive or high-risk node-negative TNBC did NOT result in a statistically significant improvement in IDFS #ASCO25 @OncoAlert
United States Trends
- 1. Massie 85.1K posts
- 2. Good Saturday 33.1K posts
- 3. GAME DAY 29.3K posts
- 4. Willie Green 3,868 posts
- 5. #Caturday 4,311 posts
- 6. #SaturdayVibes 4,852 posts
- 7. #MeAndTheeSeriesEP1 1.16M posts
- 8. #Varanasi 82.3K posts
- 9. Virginia Tech 2,140 posts
- 10. Brooklynn 2,757 posts
- 11. Senior Day 2,549 posts
- 12. James Borrego 1,328 posts
- 13. Draymond 29K posts
- 14. #GlobeTrotter 439K posts
- 15. Marjorie 104K posts
- 16. James Franklin 1,860 posts
- 17. PONDPHUWIN AT MAT PREMIERE 742K posts
- 18. Lindsey Graham 19.7K posts
- 19. Bubba 70.1K posts
- 20. Liz Cheney 6,096 posts
Something went wrong.
Something went wrong.